Metabolic cofactor and antioxidant · Fact sheet
Alpha-lipoic acid
Also known as ALA · Thioctic acid
Alpha-lipoic acid has human research on diabetic nerve symptoms. Short-term symptom improvement does not establish nerve regeneration, and a large long-term trial missed its primary endpoint.
What is Alpha-lipoic acid?
Alpha-lipoic acid participates in cellular energy metabolism. It is different from alpha-linolenic acid, a fatty acid also abbreviated ALA.
Benefits & claims
Nerve pain, glucose control, antioxidant effects, and healthy aging are common interests. Diabetic neuropathy findings cannot be generalized to every cause of nerve symptoms.
What the evidence supports
- Short-term randomized evidence supports improvement in some diabetic neuropathy symptoms.
- Long-term findings do not establish that ALA reverses nerve damage or prevents disability.
Research areas
- Diabetic polyneuropathy
- Neuropathic symptoms
- Metabolic biomarkers
Dosage & frequency
Human study contextAn oral diabetic-neuropathy trial provides a concrete study dose; it does not establish a general wellness or longevity prescription.
SYDNEY 2 randomized trial
181 patients with diabetic distal symmetric polyneuropathy
- Amount
- 600, 1,200 or 1,800 mg in separate study groups
- Frequency
- Once daily for five weeks
- Route studied or labeled
- Oral
Trial-specific neuropathy outcomes; not a general wellness regimen.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Oral alpha-lipoic acid and intravenous preparations have different evidence.
- A study of ALA does not establish equivalence for every R-ALA or racemic supplement.
Interactions & precautions
- The neuropathy trial does not provide a comprehensive interaction assessment for every diabetes medicine or ALA supplement formulation.
What is still unresolved
- Long-term benefits outside the studied neuropathy population remain uncertain.
Side effects & risks
- Nausea, vomiting, and vertigo increased with exposure in the short-term trial.
- NATHAN 1 reported more serious adverse events in the ALA group; the imbalance does not establish that every event was caused by ALA.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceThe five-week SYDNEY 2 study enrolled 181 adults with diabetic polyneuropathy. The four-year NATHAN 1 study enrolled 460 and did not significantly improve its primary combined endpoint, despite some favorable secondary findings.
Studies
181-person, five-week randomized trial with gastrointestinal and dizziness effects.
460 participants; primary endpoint not significant and secondary findings require context.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Pain: reported experiences
Less foot discomfort over several months
A person with foot neuropathy described gradual symptom improvement after adding ALA, with pain returning during a break. They had previously used gabapentin.
Reported use in this account
- Product
- Product described as ALA; formulation not stated
- Amount
- Not specified clearly
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- A few months
Other exposures described: Gabapentin earlier in the course; subsequently stopped, according to the author
The earlier gabapentin exposure and natural symptom changes cannot be separated from the reported improvement. The author's amount reply omits a unit, so no amount can be resolved; product contents were not verified.
Read the foot-symptom accountNo symptom change over several months
Another person with self-described idiopathic peripheral neuropathy reported no difference during several months of ALA use or afterward.
Reported use in this account
- Product
- Product described as ALA; formulation not stated
- Amount
- 1,800 mg
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Many months
Neuropathy type and clinical outcomes were not confirmed. This does not predict another person's response.
Read the no-improvement accountDigestion: reported experiences
Persistent heartburn
A commenter in the same discussion reported all-day heartburn when trying ALA.
Amount, frequency, route and duration could not be confirmed for this account.
The short comment omits formulation, health history and other exposures. It cannot identify the cause or frequency of heartburn.
Read the heartburn commentSensory changes: reported experiences
Less foot discomfort over several months
A person with foot neuropathy described gradual symptom improvement after adding ALA, with pain returning during a break. They had previously used gabapentin.
Reported use in this account
- Product
- Product described as ALA; formulation not stated
- Amount
- Not specified clearly
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- A few months
Other exposures described: Gabapentin earlier in the course; subsequently stopped, according to the author
The earlier gabapentin exposure and natural symptom changes cannot be separated from the reported improvement. The author's amount reply omits a unit, so no amount can be resolved; product contents were not verified.
Read the foot-symptom accountNo symptom change over several months
Another person with self-described idiopathic peripheral neuropathy reported no difference during several months of ALA use or afterward.
Reported use in this account
- Product
- Product described as ALA; formulation not stated
- Amount
- 1,800 mg
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Many months
Neuropathy type and clinical outcomes were not confirmed. This does not predict another person's response.
Read the no-improvement accountNew tingling in the feet and lower legs
A person who started ALA for arm symptoms described new pins-and-needles sensations in their feet and legs within days, still present when they posted.
Reported use in this account
- Product
- Product described as alpha-lipoic acid
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- A few days
The underlying condition and cause of the new symptoms were not assessed in this account. Temporal association does not establish an ALA reaction.
Read the new-tingling accountNo clear change: reported experiences
No symptom change over several months
Another person with self-described idiopathic peripheral neuropathy reported no difference during several months of ALA use or afterward.
Reported use in this account
- Product
- Product described as ALA; formulation not stated
- Amount
- 1,800 mg
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Many months
Neuropathy type and clinical outcomes were not confirmed. This does not predict another person's response.
Read the no-improvement accountApproval status
Alpha-lipoic acid has no FDA-approved drug indication for the wellness uses discussed here. Supplement availability is not premarket FDA approval of effectiveness or safety.
Supplement research is not FDA drug approval
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Long-term effects on disability or nerve regeneration
- Applicability to non-diabetic neuropathy
- Safety and interactions across preparations
Summary
Long-term findings do not establish that ALA reverses nerve damage or prevents disability.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedSYDNEY 2: alpha-lipoic acid and diabetic neuropathy symptoms
181-person, five-week randomized trial with gastrointestinal and dizziness effects.
- pubmedNATHAN 1: four-year alpha-lipoic acid trial
460 participants; primary endpoint not significant and secondary findings require context.
- fdaFDA: what approval means for supplements
Dietary supplements are not approved by FDA for safety and effectiveness before marketing.